scholarly journals A case of Stage I exophytic tongue cancer with early poor prognosis

2013 ◽  
Vol 25 (4) ◽  
pp. 199-205
Author(s):  
Toru Inomata ◽  
Kayo Nakau ◽  
Syuhei Okamoto ◽  
Hisashi Okamura ◽  
Hirohumi Shoji ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Tongue Cancer ◽  
Stage I

scholarly journals Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma

2001 ◽  
Vol 12 (8) ◽  
pp. 1121-1125 ◽  
Author(s):  
Y. Saijo ◽  
G. Sato ◽  
K. Usui ◽  
M. Sato ◽  
M. Sagawa ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Poor Prognosis ◽  
Nucleolar Protein ◽  
Stage I

scholarly journals Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Shilpi Gupta ◽  
Prabhat Kumar ◽  
Harsimrut Kaur ◽  
Nishi Sharma ◽  
Daman Saluja ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Tongue Cancer ◽  
Aggressive Tumor ◽  
Tumor Phenotypes

Treatment of stage I and II oral tongue cancer

Head & Neck ◽  
1993 ◽  
Vol 15 (4) ◽  
pp. 308-312 ◽  
Author(s):  
Daniel D. Lydiatt ◽  
K. Thomas Robbins ◽  
Robert M. Byers ◽  
Patricia F. Wolf
Keyword(s):  
Tongue Cancer ◽  
Stage I ◽  
Oral Tongue ◽  
Oral Tongue Cancer

High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis

2015 ◽  
Vol 67 (5) ◽  
pp. 664-676 ◽  
Author(s):  
Cindy Neuzillet ◽  
Anne Couvelard ◽  
Annemilaï Tijeras-Raballand ◽  
Louis de Mestier ◽  
Armand de Gramont ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Poor Prognosis ◽  
Stage I ◽  
Scoring Method

Follicular lymphoma: prognostic factors for response and survival.

1986 ◽  
Vol 4 (10) ◽  
pp. 1470-1480 ◽  
Author(s):  
C J Gallagher ◽  
W M Gregory ◽  
A E Jones ◽  
A G Stansfeld ◽  
M A Richards ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Poor Prognosis ◽  
Single Agent ◽  
Stage Iv ◽  
Poor Response ◽  
Stage I ◽  
Stage Ii ◽  
Response To Treatment ◽  
Stage Iv Disease ◽  
Short Courses

One hundred forty-eight patients with newly diagnosed follicular lymphoma were treated over a 12-year period. Twenty-two patients received radiotherapy for stage I and II disease, followed by adjuvant chemotherapy in 14 patients. One hundred thirteen were treated at presentation with short courses of chemotherapy, most often with single-agent chlorambucil for bulky stage II and stages III and IV disease. Thirteen patients were managed expectantly until there was evidence of disease progression. The median survival was 9 years. Patients treated with radiotherapy for stage I and II disease had an 83% relapse-free survival, but those with bulky stage II or stages III and IV disease treated with chemotherapy pursued a remitting and relapsing course with a 70% response rate at initial and subsequent retreatments, but a median duration of remission of 4 years in stage III and 1 year in stage IV disease (P = .041). Patients were observed in relapse and retreatment was administered as appropriate, once every 33 months on average. Poor prognosis patients could be identified by a combination of the presentation characteristics: B symptoms, hepatosplenomegaly, anemia, and abnormal liver function. These factors predicted a poor response to treatment and correlated with a short survival. Histologic subgroups were not associated with differences in survival, but transformation to a diffuse high-grade lymphoma was observed in 23 of the 72 patients (32%) at risk, with a median follow-up of 6 years and 6 months, and was associated with a very poor prognosis. The present treatment strategy has proved successful for most patients with localized disease and those older patients with indolent small volume disseminated follicular lymphoma. New approaches are being investigated for the younger poor prognosis patients.

Analysis of Variance Based Significance Analysis of Cartilage Tumor

2020 ◽  
Vol 10 (9) ◽  
pp. 1985-1991
Author(s):  
Yuan Li ◽  
Zili Xu ◽  
Xiangyang Liu ◽  
Xiandong Peng ◽  
Shu Cao ◽  
...  
Keyword(s):  
Protein Expression ◽  
Poor Prognosis ◽  
Histological Grade ◽  
Stage I ◽  
Stage Iii ◽  
Ajcc Stage ◽  
Kaplan Meier ◽  
First Choice ◽  
Clinicopathological Significance ◽  
Enneking Stage

Chondrosarcoma is a malignant bone tumor with poor prognosis. Surgical treatment is the first choice for chondrosarcomas. Chondrosarcoma is not sensitive to chemotherapy and radiotherapy. Identification of biological markers is important for the early diagnosis and targeted treatment of chondrosarcoma. This study aimed to investigate the protein expression and clinicopathological significance of APEX1 and Haptoglobin in 85 chondrosarcomas and 38 osteochondromas based on deep learning. The APEX1 and Haptoglobin protein expression in tissues was measured by immunohistochemistry. The percentage of positive APEX1 and Haptoglobin expression was significantly higher in patients with chondrosarcoma than in patients with osteochondroma (P < 0001). The percentage of positive APEX1 and Haptoglobin expression was significantly lower in patients with histological grade I, AJCC stage I, Enneking stage I and non-metastatic chondrosarcoma than patients with histological grade III, AJCC stage III+IV, Enneking stage III, and metastatic chondrosarcoma (P < 0005 or P < 0001). APEX1 expression was positively correlated with Haptoglobin expression in chondrosarcoma (P < 0001). Kaplan—Meier survival analysis demonstrated that histological grade, AJCC stage, Enneking stage, metastasis, invasion, and APEX1 and Haptoglobin expression significantly correlated with a short mean survival time of patients with chondrosarcoma (P < 0005 or P < 0001). Cox multivariate analysis showed that positive APEX1 and Haptoglobin expressions were independent prognostic factors that negatively correlated with postoperative survival and positively correlated with mortality. The AUC for APEX1 (AUC = 0.673, 95% CI: 0.573—0.772), or Haptoglobin (AUC = 0.649, 95% CI: 0.548—0.750), respectively. Positive APEX1 and Haptoglobin expression is associated with the carcinogenesis, progression and poor prognosis of chondrosarcoma.

Prognostic impact of preoperative albumin to globulin ratio in curative colon cancer patients.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 647-647
Author(s):  
Yuji Toiyama ◽  
Hiroyuki Fujikawa ◽  
Yasuhiro Inoue ◽  
Hiroki Imaoka ◽  
Masato Okigami ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Early Recurrence ◽  
Stage I ◽  
Stage Iii ◽  
Prognostic Impact ◽  
Stage Iii Colon Cancer ◽  
Albumin To Globulin Ratio

647 Background: Albumin to globulin ratio (AGR) has been reported to predict long term mortality in patients with several cancers. However, prognostic impact of preoperative AGR in colon cancer patients with curative intent has not yet been fully addressed. Therefore, we, for the first time, investigated the association between AGR and clinico-pathological findings including overall survival (OS) and disease free survival (DFS) in stage I-III colon cancer patients. Methods: Clinicopathological findings including preoperative laboratory data (carcinoembryonic antigen [CEA] and AGR) from 251 curative colon cancer patients were assessed as indicators of early recurrence and poor prognosis in this retrospective study. AGR was calculated as [AGR = albumin/ (total protein - albumin)]. The cut-off value of AGR was 1.32 in current study. Results: Several clinicopathological categories related with tumor progression such as lymph node metastasis, T4 tumor, large tumor size, undifferentiated tumor, venous and lymphatic invasion, and high CEA were significantly associated with low AGR level. The patients with low AGR were significantly poorer OS (P = 0.001) and DFS (P = 0.003) than those with high AGR, respectively. In addition, multivariate analyses demonstrated that low AGR was independently associated with early recurrence (HR = 2.87, P = 0.007) and poor prognosis (HR = 2.56, P = 0.008), respectively. On the other hand, sub analysis of survival curves revealed that stage III colon cancer patients with low AGR were significantly poorer OS (P = 0.007) and DFS (P = 0.02) than those with high AGR, respectively. Furthermore, significantly poorer OS and DFS were also shown in stage I-II colon cancer patients with low AGR, respectively (OS: P = 0.02, DFS: P = 0.01). Conclusions: Preoperative AGR was an independent predictor of early recurrence and poor prognosis in curative colon cancer patients. AGR may represent a simple, potentially useful predictive biomarker for selecting stage I-II colon cancer patients who might need adjuvant chemotherapy. Furthermore, AGR may select candidates who are better to introduce more intensive adjuvant chemotherapy after curative operation in stage III colon cancer patients.

Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma

Cancer ◽  
2008 ◽  
Vol 112 (2) ◽  
pp. 345-351 ◽  
Author(s):  
Kyle Rusthoven ◽  
Ari Ballonoff ◽  
David Raben ◽  
Changhu Chen
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Poor Prognosis ◽  
Tongue Squamous Cell Carcinoma ◽  
Stage I ◽  
Oral Tongue
Sign in / Sign up

Export Citation Format

Share Document